SG11201502104YA - Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium - Google Patents
Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospiumInfo
- Publication number
- SG11201502104YA SG11201502104YA SG11201502104YA SG11201502104YA SG11201502104YA SG 11201502104Y A SG11201502104Y A SG 11201502104YA SG 11201502104Y A SG11201502104Y A SG 11201502104YA SG 11201502104Y A SG11201502104Y A SG 11201502104YA SG 11201502104Y A SG11201502104Y A SG 11201502104YA
- Authority
- SG
- Singapore
- Prior art keywords
- trospium
- treatment
- methods
- drug delivery
- delivery systems
- Prior art date
Links
- 208000026723 Urinary tract disease Diseases 0.000 title 1
- 238000012377 drug delivery Methods 0.000 title 1
- 230000004064 dysfunction Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 title 1
- 229960001491 trospium Drugs 0.000 title 1
- 208000014001 urinary system disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702576P | 2012-09-18 | 2012-09-18 | |
| PCT/US2013/060479 WO2014047221A1 (en) | 2012-09-18 | 2013-09-18 | Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201502104YA true SG11201502104YA (en) | 2015-05-28 |
Family
ID=49301639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502104YA SG11201502104YA (en) | 2012-09-18 | 2013-09-18 | Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10500200B2 (en) |
| EP (1) | EP2897616A1 (en) |
| JP (2) | JP6600256B2 (en) |
| KR (1) | KR102141433B1 (en) |
| CN (2) | CN104684556A (en) |
| AU (1) | AU2013318146B2 (en) |
| BR (1) | BR112015005351A2 (en) |
| CA (1) | CA2883855C (en) |
| IL (1) | IL237498B (en) |
| MX (2) | MX2015003110A (en) |
| RU (1) | RU2670749C9 (en) |
| SG (1) | SG11201502104YA (en) |
| WO (1) | WO2014047221A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8721621B2 (en) | 2009-09-10 | 2014-05-13 | Taris Biomedical, Inc. | Systems and methods for deploying devices to genitourinary sites |
| PL2890384T3 (en) | 2012-08-31 | 2022-02-14 | Taris Biomedical Llc | Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin |
| BR112015004110A2 (en) | 2012-08-31 | 2017-07-04 | Taris Biomedical Llc | prostate drug delivery systems and methods |
| CN104684556A (en) * | 2012-09-18 | 2015-06-03 | 塔里斯生物医药公司 | Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium |
| EP3597176A1 (en) | 2014-08-19 | 2020-01-22 | The Regents Of The University Of California | Implants for localized drug delivery and methods of use thereof |
| GB201506526D0 (en) | 2015-04-17 | 2015-06-03 | Uropharma Ltd And Synesis Llc | Medicinal composition |
| CN106706832A (en) * | 2015-08-06 | 2017-05-24 | 舒泰神（北京）生物制药股份有限公司 | Method for determining content of trospium chloride |
| HUE054587T2 (en) * | 2017-02-01 | 2021-09-28 | Taris Biomedical Llc | In vivo drug delivery devices |
| WO2020028554A1 (en) * | 2018-08-01 | 2020-02-06 | Taris Biomedical Llc | Methods of treating overactive bladder using trospium |
| WO2020222139A1 (en) * | 2019-04-30 | 2020-11-05 | Trigone Pharma Ltd. | Formulations and methods for drug instillation into the bladder and treatment of bladder ailments |
| US11338119B2 (en) | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11173291B2 (en) | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11344526B2 (en) | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| KR102596697B1 (en) | 2021-05-20 | 2023-11-01 | 김정우 | Cosmetic composition containing Orostachys japonicus extract as an active ingredient and method for manufacturing cosmetic composition |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2125696T3 (en) * | 1996-11-27 | 1999-03-01 | Pfleger R Chem Fab | USE OF TROPSY CHLORIDE FOR THE PRODUCTION OF A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF VESIC DYSFUNCTIONS. |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| AU2003286129A1 (en) * | 2002-12-11 | 2004-06-30 | Coloplast A/S | A urinary catheter device with a pharmaceutically active composition |
| WO2004064789A2 (en) | 2003-01-16 | 2004-08-05 | University Of Rochester | Quaternary antimuscarinic compounds for the treatment of bladder diseases |
| ES2322148T3 (en) | 2004-08-11 | 2009-06-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | MEDICINES CONTAINING ANTI-POLINERGIC FOR TREATMENT IN URINARY ROADS. |
| WO2006101954A2 (en) * | 2005-03-17 | 2006-09-28 | Indevus Pharmaceuticals, Inc. | Interstitial cystitis treatment |
| US7390816B2 (en) | 2005-06-21 | 2008-06-24 | Bridge Pharma, Inc. | Methods for treating urinary incontinence in patients suffering from memory disorders |
| DK1933810T3 (en) | 2005-08-11 | 2013-01-28 | Childrens Medical Center | Intravesical drug delivery device and method |
| US20100003297A1 (en) | 2005-08-11 | 2010-01-07 | Massachusetts Institute Of Technology | Implantable Drug Delivery Device and Methods of Treating Male Genitourinary and Surrounding Tissues |
| EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| JP5560200B2 (en) | 2007-12-11 | 2014-07-23 | マサチューセッツ インスチテュート オブ テクノロジー | Implantable drug delivery device for treating bladder and other body vesicles or lumens |
| AU2010265866B2 (en) | 2009-06-26 | 2012-07-12 | Taris Biomedical Llc | Solid drug tablets for implantable drug delivery devices |
| US8721621B2 (en) | 2009-09-10 | 2014-05-13 | Taris Biomedical, Inc. | Systems and methods for deploying devices to genitourinary sites |
| US9017312B2 (en) | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
| DK2512581T3 (en) | 2009-12-17 | 2021-03-29 | Taris Biomedical Llc | IMPLANTABLE DECORATION WITH INTRAVESICAL TOLERANCE |
| US20110218488A1 (en) | 2010-03-05 | 2011-09-08 | Taris Biomedical, Inc. | Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites |
| WO2012048104A1 (en) | 2010-10-06 | 2012-04-12 | Taris Biomedical, Inc. | Implantable drug delivery device with bladden retention feature |
| JP5945544B2 (en) * | 2010-10-06 | 2016-07-05 | タリス バイオメディカル エルエルシー | Time-selective bioabsorbable or disintegratable drug delivery system and method |
| AU2012205654B2 (en) | 2011-01-10 | 2016-09-08 | Allergan, Inc. | Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding |
| US9107816B2 (en) * | 2011-02-04 | 2015-08-18 | Taris Biomedical Llc | Implantable device for controlled dissolution and diffusion of low solubility drug |
| CN104684556A (en) * | 2012-09-18 | 2015-06-03 | 塔里斯生物医药公司 | Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium |
| NZ711546A (en) | 2013-03-15 | 2017-12-22 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
-
2013
- 2013-09-18 CN CN201380046758.2A patent/CN104684556A/en active Pending
- 2013-09-18 BR BR112015005351A patent/BR112015005351A2/en not_active Application Discontinuation
- 2013-09-18 MX MX2015003110A patent/MX2015003110A/en unknown
- 2013-09-18 AU AU2013318146A patent/AU2013318146B2/en active Active
- 2013-09-18 EP EP13771696.5A patent/EP2897616A1/en active Pending
- 2013-09-18 SG SG11201502104YA patent/SG11201502104YA/en unknown
- 2013-09-18 CA CA2883855A patent/CA2883855C/en active Active
- 2013-09-18 KR KR1020157008403A patent/KR102141433B1/en active IP Right Grant
- 2013-09-18 JP JP2015532177A patent/JP6600256B2/en active Active
- 2013-09-18 WO PCT/US2013/060479 patent/WO2014047221A1/en active Application Filing
- 2013-09-18 CN CN202010161062.6A patent/CN111450093A/en active Pending
- 2013-09-18 RU RU2015112196A patent/RU2670749C9/en active
-
2015
- 2015-03-02 IL IL237498A patent/IL237498B/en active IP Right Grant
- 2015-03-11 MX MX2020002465A patent/MX2020002465A/en unknown
- 2015-03-16 US US14/658,699 patent/US10500200B2/en active Active
-
2018
- 2018-02-02 JP JP2018017300A patent/JP2018080208A/en active Pending
-
2019
- 2019-12-06 US US16/706,009 patent/US11850244B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014047221A1 (en) | 2014-03-27 |
| US10500200B2 (en) | 2019-12-10 |
| CA2883855A1 (en) | 2014-03-27 |
| RU2670749C9 (en) | 2018-12-13 |
| AU2013318146B2 (en) | 2018-05-10 |
| RU2015112196A (en) | 2016-11-10 |
| WO2014047221A9 (en) | 2015-05-21 |
| MX2020002465A (en) | 2020-07-13 |
| BR112015005351A2 (en) | 2017-07-04 |
| JP2015529688A (en) | 2015-10-08 |
| MX2015003110A (en) | 2015-06-05 |
| KR20150058271A (en) | 2015-05-28 |
| JP6600256B2 (en) | 2019-10-30 |
| US20150182516A1 (en) | 2015-07-02 |
| US11850244B2 (en) | 2023-12-26 |
| JP2018080208A (en) | 2018-05-24 |
| US20200108057A1 (en) | 2020-04-09 |
| RU2670749C2 (en) | 2018-10-25 |
| CA2883855C (en) | 2020-09-15 |
| AU2013318146A1 (en) | 2015-03-19 |
| EP2897616A1 (en) | 2015-07-29 |
| CN111450093A (en) | 2020-07-28 |
| IL237498B (en) | 2018-01-31 |
| IL237498A0 (en) | 2015-04-30 |
| KR102141433B1 (en) | 2020-08-05 |
| CN104684556A (en) | 2015-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237498A0 (en) | Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium | |
| EP2785275A4 (en) | Treatment of urinary incontinence | |
| HK1198297A1 (en) | Compositions, uses and methods for treatment of metabolic disorders and diseases | |
| EP2675402A4 (en) | Blood flow disruption devices and methods for the treatment of vascular defects | |
| EP2731658A4 (en) | Device for delivery of antimicrobial agent into trans-dermal catheter | |
| EP2704630A4 (en) | System and method for tracking brain states during administration of anesthesia | |
| EP2552357A4 (en) | Medical device for treatment of urinary incontinence in females | |
| HK1202313A1 (en) | Methods and compositions for the treatment and diagnosis of bladder cancer | |
| EP2782631A4 (en) | Implantable solid-liquig drug delivery apparatus, formulations, and methods of use | |
| AU339607S (en) | Medical device for treatment of sleep disorders | |
| IL229474A0 (en) | Cannabinoids for use in the treatment of neuropatich pain | |
| IL237300B (en) | Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine | |
| HK1197276A1 (en) | Methods and compositions for the treatment and diagnosis of bladder cancer | |
| HK1208830A1 (en) | Drug delivery device for the treatment of patients with respiratory diseases | |
| IL227312A0 (en) | Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding | |
| IL237281B (en) | Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin | |
| EP2678068A4 (en) | Drug releasing pelvic treatment system and method | |
| ZA201403767B (en) | Implantable drug delivery compositions and methods of treatment | |
| GB2496688B (en) | Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases | |
| ZA201502288B (en) | Ciclesonide for treatment of airway disease in horses | |
| EP2763716A4 (en) | Solid drug delivery apparatus, formulations and methods of use | |
| EP2726079A4 (en) | Method of administration and treatment | |
| EP2790637A4 (en) | Vaginal drug delivery devices and manufacturing methods | |
| EP2673372A4 (en) | Methods of prognosing and administering treatment for inflammatory disorders | |
| HK1210209A1 (en) | Treatment of diseases of endothelial dysfunction and inflammation |